OBJECTIVE Discuss the importance of clinical pharmacists and pharmacy care during anti-infective therapy in critically ill patients.METHODS Clinical pharmacists involved in the treatment process of a case of critically ill patients, who has craniocerebral injury, multiple organ insufficiency, severe infection, electrolyte imbalance, venous thrombosis of both lower extremities, anemia, and gastrointestinal bleeding. Pharmacy care includes adjustment of anti-infective treatment,reduce adverse drug reactions and maintain homeostasis, et al. RESULTS The patient was cured and in a stable condition after systematic treatment. CONCLUSION Clinical pharmacists could play an important role in improving the prognosis of critically ill patients.
YU A R, FAN X, ZHOU F, et al. Breakthrough points of pharmaceutical care in anti-infection treatment by clinical pharmacists[J]. China Pharm(�й�ҩʦ),2014,17(10):1724-1728.
[2]
POON W S, NG S, WAI S. CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study intracranial pressure and neuromonitoring in brain injury[J]. Vienna, 1998: 146-148.
[3]
LIU L, FANG L Z, FU W P, et al. Efficacy and safety evaluation of teicoplanin on hospital-acquired pneumonia with renal dysfunction[J]. Chin J Nosocom(�л�ҽԺ��Ⱦѧ��־),2010,20(9):1307-1309.
[4]
LIU Y N. Expert opinion on the diagnosis and treatment of pseudomonas aeruginosa lower respiratory tract infection[J]. Chin J Tuber Respir Dis(�л���˺ͺ�����־), 2014,37(1):9-15.
[5]
CUNHA B A. Antibiotic side effects[J]. Med Clin North Ame, 2001, 85(1): 149-185.
[6]
WANG M G. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement [J]. Chin J Infect Chemother(�й���Ⱦ�뻯����־), 2017,17(1):82-92
[7]
KALIL A C, METERSKY M L, KLOMPAS M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63(5):61-111.
[8]
HANG X, DENG Z D, NI Y X, et al. Chinese experts′consensus on prevention and control of multidrug resist-ance organism healthcare-associated infection [J]. Chin J Infect Control(�й���Ⱦ������־), 2015,14(1):1-8.
[9]
LIMPER A H, KNOX K S, SAROSI G A, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients[J]. Am J Resp Critical Care Med, 2011,183(1):96-128.
[10]
ZHENG J H. Chinese experts consensus in urinary tract infection diagnosis and treatment (2015 Edition)[J]. Chin J Urol(�л����������־), 2015,36(4):245-248.
[11]
PFALLER M A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment[J]. Am J Med, 2012, 125(1): 3-13.
[12]
WESTPHAL J F, VETTER D, BROGARD J M. Hepatic side-effects of antibiotics[J]. J Antimicrob Chemoth, 1994,33(3): 387-401.
[13]
TABER S S, MUELLER B A. Drug-associated renal dysfunction[J]. Critical Care Clin, 2006,22(2):357-374.
[14]
BARTLETT J G. Antibiotic-associated diarrhea[J]. New Engl J Med, 2002, 346(5): 334-339.
[15]
ASTER R H, BOUGIE D W. Drug-induced immune thrombocytopenia[J]. New Engl J Med, 2007,357(6):580-587.
[16]
GONÇALVES-PEREIRA J, PÓVOA P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams[J]. Critical Care, 2011,15(5):1-17.
[17]
ROBERTS J A, ROBERTS M S, SEMARK A, et al. Antibiotic dosing in the′at risk′critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients[J]. BMC Anesthe, 2011,11(1): 3.
[18]
ULLDEMOLINS M, ROBERTS J A, LIPMAN J, et al. Antibiotic dosing in multiple organ dysfunction syndrome[J]. Chest,2011, 139(5):1210-1220.
[19]
SCAGLIONE F, PARABONI L. Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens[J]. Int J Antimicrob Agents,2008,32(4):294-301.
2018, Vol. 53 
